Navigation Links
Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
Date:12/4/2009

NEW YORK, Dec. 4 /PRNewswire/ -- Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009. The poster will be presented by Stemline's collaborators at The University of Texas M.D. Anderson Cancer Center.

The data demonstrate in vitro and in vivo activity of both SL-401 and SL-501 against CML and CML cancer stem cells as single agents, and in combination with tyrosine kinase inhibitors (TKIs). Results also include activity of these IL-3R targeting agents against CML cells with mutations that render them resistant to TKIs.

Details on the abstract selected for presentation are as follows:


Abstract #:          2172

TITLE:               Targeting IL-3 Receptor in Chronic Myeloid Leukemia

Lead Author          Olga Frolova, MD, PhD

Session Name         Chronic Myeloid Leukemia -Biology and Pathophysiology
                     excluding Therapy Poster I

Date                 Sunday, December 6, 2009

Presentation Time:   6:00PM - 8:00PM

Location:            Hall E (Ernest N. Morial Convention Center)

Poster Board no.:    II-149

A copy of the above referenced abstract can be viewed online through the ASH website (www.hematology.org).

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor which is expressed on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I/II clinical trial. Stemline is also developing a proprietary portfolio of biological and small molecule compounds directed at high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has built a robust discovery platform called StemScreen® which the Company has utilized to identify candidate compounds that target cancer stem cells. For more information, please visit the Company's website at www.stemline.com.


Stemline Contact:
Tom Cirrito, PhD
Director of Operations
Stemline Therapeutics, Inc.
Tel: 212-531-5976
Email: tcirrito@stemline.com

SOURCE Stemline Therapeutics, Inc.


'/>"/>
SOURCE Stemline Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Stemline Therapeutics Raises $12.5 Million
2. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Kinder ... several positive developments that position the Company for the future. Kinder Scientific ... Craig F. Kinghorn has been appointed Chairman of the Board, Curtis D. Kinghorn ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Ankle ... plating options designed to address fractures of the distal tibia and fibula. This ... Acumed Ankle Plating System 3 is composed of seven plate families that span ...
(Date:5/25/2016)... ... 2016 , ... WEDI, the nation’s leading authority on the use of health ... has been named by the WEDI Board of Directors as WEDI’s president and CEO. ... with more than 35 years of experience in healthcare, association management and organizational leadership, ...
(Date:5/24/2016)... , May 24, 2016   MedyMatch Technology Ltd ., ... artificial intelligence, real-time decision support tools in the emergency room, ... the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference. ... Israel,s 15th National Life Sciences and Technology Week, ... David Intercontinental Hotel in Tel Aviv, Israel ...
Breaking Biology Technology:
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
Breaking Biology News(10 mins):